Identification of New *Mycobacterium tuberculosis* Proteasome Inhibitors Using a Knowledge-Based Computational Screening Approach

Tahani M. Almeleebia 1, Mesfer Al Shahrani 2, Mohammad Y. Alshahrani 2-3, Irfan Ahmad 2, Abdullah M. Alkahtani 4, Md Jahoor Alam 5, Mohammad Adnan Kausar 6, Amir Saeed 7,8, Mohd Saeed 5 and Sana Iram 9,10,*

Abstract: *Mycobacterium tuberculosis* (Mtb) is a deadly tuberculosis (TB)-causing pathogen. The proteasome is vital to the survival of Mtb and is therefore validated as a potential target for anti-TB therapy. Mtb resistance to existing antibacterial agents has enhanced drastically, becoming a worldwide health issue. Therefore, new potential therapeutic agents need to be developed that can overcome the complications of TB. With this purpose, in the present study, 224,205 natural compounds from the ZINC database have been screened against the catalytic site of Mtb proteasome by the computational approach. The best scoring hits, ZINC3875469, ZINC4076131, and ZINC1883067, demonstrated robust interaction with Mtb proteasome with binding energy values of −7.19, −7.95, and −8.05 kcal/mol for the monomer (K-chain) and −8.05, −9.10, and −7.07 kcal/mol for the dimer (both K and L chains) of the beta subunit, which is relatively higher than that of reference compound HT1171 (−5.83 kcal/mol (monomer) and −5.97 kcal/mol (dimer)). In-depth molecular docking of top-scoring compounds with Mtb proteasome reveals that amino acid residues Thr1, Arg19, Ser20, Thr21, Glu22, Gly23, Asn24, Lys33, Gly47, Asp124, Ala126, Trp129, and Ala180 are crucial in binding. Furthermore, a molecular dynamics study showed steady-state interaction of hit compounds with Mtb proteasome. Computational prediction of physicochemical property assessment showed that these hits are non-toxic and possess good drug-likeness properties. This study proposed that these compounds could be utilized as potential inhibitors of Mtb proteasome to combat TB infection. However, there is a need for further bench work experiments for their validation as inhibitors of Mtb proteasome.

Keywords: *Mycobacterium tuberculosis*; tuberculosis; proteasome; natural compounds
1. Introduction

*Mycobacterium tuberculosis* (Mtb) is a deadly tuberculosis (TB)-causing pathogen. TB is a communicable disease that ranks in the world’s top 10 causes of death. Besides, it is the leading cause of single infectious agent fatality (higher than HIV/AIDS), and approximately 10 million people fell ill with TB in 2019 [1]. A person with a weakened immune system is highly susceptible to TB infection; thus, their involvement with HIV is the major cause of fatality for these patients [2]. Mtb resistance to existing antibacterial agents has enhanced drastically as well as multidrug-resistant and extensively drug-resistant Mtb strains. These strains are becoming a worldwide health issue [3,4] and are involved in the host immune system’s resistance to nitric oxide stress.

Proteasomes are multi-subunit proteolytic complexes that have a vital role in various cellular functions. Proteasome inhibition has appeared as a prevailing approach for the management of various infectious diseases [5]. Mtb proteasome is vital for the bacterium pathogenesis; hence, it is regarded as an attractive target for the development of new agents that may inhibit Mtb. The Mtb mutants lacking the proteasome (proteasome subunits silencing) are viable in vitro, but the infection cannot be maintained in the TB mouse model [6,7]. Hence, it seems that Mtb proteasomes are vital for their propagation in mammalian hosts and are involved in the host immune system’s resistance to nitric oxide stress [8].

The proteasome is a heap-shaped protein made up of four rings of heptamers. Its length and width are 150 and 115 Å, respectively [9,10]. Inner beta rings are formed by seven identical prcB subunits, and outer alpha rings are formed by seven identical prcA subunits, which give a path to inner beta rings with active sites when they are open. As a result, it provides the overall organization of α7β7β7α7. The active site of the bacterial proteasome is identical to that of the archaeal and eukaryotic proteasomes and is found primarily in β subunits [9,11].

In the literature, several effective Mtb proteasome inhibitors have been documented. Among them, HT1171, GL5, MLN273, and fellutamide-B are the most potent Mtb proteasome inhibitors [9,12,13]. The Mtb proteasome was revealed to be inhibited by 15 psoralens from a library of 92 analogs, and compounds 8, 11, 13, and 15 exhibited potent inhibition in a fluorescence-based enzymatic assay [14]. Several plant-derived natural products were discovered to inhibit Mtb proteasome with IC₅₀ values ranging from 25 to 120 M using the chymotrypsin substrate Suc-LLVY-AMC [15]. Various bortezomib analogs have been developed, with the phenol- and halogen-substituted analogs being more specific for the Mtb proteasome than the human proteasome [16].

Drug development requires the identification of some potential hits from a huge library of chemical components. Screening such a huge compounds library using wet-lab assays can be a difficult task. Protein-ligand docking is a powerful tool in drug development because it aids in the identification of active or lead compounds from a library of compounds [17,18]. This method is also capable of accurately identifying inhibitor binding modes to the target proteins [17,19]. Computational screening before laboratory testing is a successful approach in decreasing the number of candidate inhibitors for benchwork-based screening [20–22]. The present study aimed to identify new possible hits from the natural compounds databases using in silico, state-of-the-art techniques that could serve as Mtb proteasome inhibitors to combat TB infection.

2. Methodology

2.1. Protein Structure Preparation

Mtb proteasome 3D structure (PDB ID: 5TRG) was retrieved from the protein data bank and prepared in monomer form by Discovery Studio (DS) 2020. Since the Mtb proteasome core particle has 14 chains in the beta subunit, all of which have the same active sites, the present study focused on chain K as a monomer, and the K and L chains as a dimer.
2.2. Database Collection and Refinement

Natural compounds were accessed from the ZINC database (https://zinc.docking.org accessed on 29 January 2021), limiting the outcomes by choosing “natural products” as a subset, resulting in a total of 224,205 compounds and was then downloaded in SDF format. Furthermore, these compounds were processed for minimization and preparation for screening using the “ligand preparation” tool in DS 2020.

2.3. Receptor-Based Virtual Screening

In order to identify possible leads, the prepared librarian was screened against the Mtb proteasome active site using AutoDock vina (version 1.1.2). Then, the top-scored hits were further processed for in-depth molecular docking studies.

2.4. Molecular Docking

Lead hits were docked with Mtb proteasome (monomer; K-chain) by Autodock4.2 to determine the ligand–protein interaction and their binding affinities [23]. All input files were prepared using AutoDock Tools, adding polar hydrogen in protein, and assigning the charges with the Kollman charges method. The grid center points X, Y, and Z were kept as 36.731, −11.255, and 43.313, respectively. Grid points were fixed as 60 × 60 × 60 Å with the spacing of 0.375 Å. Additionally, these hits were also docked with the dimer form (K and L chains) of the beta subunit of the Mtb proteasome, keeping the grid center points X, Y, and Z as 41.22, 0.60, and 32.31, respectively. All docking calculation parameters were kept as a default value. The highest negative binding energy (BE) value was ranked as the most promising binding pose.

2.5. LIGPLOT+ Analysis

The H-bond and hydrophobic interactions between “hit compounds–Mtb proteasome” complexes were determined by the LIGPLOT+ Version v.2.1. The 3-D structures of the “compound–Mtb proteasome” interaction produced were transformed into 2-D figures using the LIGPLOT algorithm.

2.6. Drug-Likeness

Top-scoring molecules (ZINC3875469, ZINC4076131, and ZINC1883067) were further used to estimate drug-likeness, toxicity, and pharmacokinetic properties using the pkCSM and SwissADME tools [24]. SMILE IDs of the molecules retrieved from the ZINC database were entered into the pkCSM tool to evaluate drug-likeness [25].

2.7. Molecular Dynamics (MD) Simulations

To study the dynamic behavior of the protein–ligand complex in simulated physiological conditions, MD simulations were performed using Gromacs Ver. 2020.4. The protein–ligand complexes were solvated in a 10 × 10 × 10 Å orthorhombic periodic box built with TIP3P water molecules. By adding a sufficient number of 9 Na counterions, the entire system was neutralized. This solvated system was energy-minimized and position-restrained with CHARMM 36 as a force-field [26]. Further, 20 ns of MD run was carried out at 1 atm pressure and 300 K temperature implementing NPT ensemble with a recording interval of 100 ps. This resulted in a total of 1000 reading frames. In the end, various parameters of MD simulation study such as ligand binding site analysis, root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), radius of gyration, Mindistance, H-bond analysis, etc., were analyzed for the stability, compactness, structural variations, and protein–ligand interactions in the solvated system.
3. Results and Discussion

3.1. Virtual Screening, Molecular Docking, and LIGPLOT

Mtbc is the only known bacterial pathogen that has proteasome activity [6]. The increase in drug-resistant TB is a major public health concern and requires the development of new agents that can evade the resistance and effectively control TB. With this purpose, we conducted the computational screening of 224,205 natural compounds from the ZINC database targeting the Mtbc proteasome. Among them, the selected hits ZINC3875469, ZINC4076131, and ZINC1883067 showed strong binding with the Mtbc proteasome. Two-dimensional structures of hit compounds are shown in Figure 1. ZINC3875469 interacted with proteasome through 10 amino acid residues: Thr1, Ser20, Thr21, Gln22, Ala46, Gly47, Gly140, and Ser141 (Figure 2a); while Thr1, Arg19, Ser20, Asn24, Thr21, Gln22, Gly23, Asn24, Lys33, Gly47, Ala49, and Ala180 residues of the proteasome were observed to bind with ZINC4076131 (Figure 2b). In a similar way, ZINC1883067 was found to interact with Thr1, Arg19, Ser20, Thr21, Lys33, Ala46, Gly47, Gly140, Ser141, and Ala180 residues of the proteasome (Figure 2c).

![Figure 1. 2D structures of hit compounds.](image)

The active site pocket residues of Mtbc proteasome were determined as Ser20, Thr21, Gln22, Val31, Ile45, Ala46, Thr48, Ala49, Val53, Asp124, Asp128, and Asp130 [27]. Interestingly, ZINC3875469, ZINC4076131, and ZINC1883067 were also found to bind with these residues of Mtbc proteasome. In a study, small molecules were reported to interact with Thr1, Arg19, Ser20, Thr21, Gln22, Lys33, Gly47, Ala49, Gly140, and Ser141 residues of Mtbc proteasome [27]. Consistent with this, in the present study, the selected hits were observed to bind with the similar residues of Mtbc proteasome.

Oxathiazol-2-one compounds altered the Mtbc proteasome by interacting with the Thr1 residues of the core complex beta-subunit. Consequently, Thr1 is cyclocarbonylated, which greatly alters the active site environment and causes an alternative protein conformation in which the substrate-binding pocket is disrupted. As a result, Mtbc proteasome substrates were unable to obtain access to the proteasome, causing toxic proteins and peptides to accumulate within mycobacterial cells. Notably, the oxathiazol-2-one compounds were thought to have no effect on the substrate-binding pocket of human proteasomal beta-subunits. It was proposed that this was due to the fact that the residues involved in preserving the altered conformation were largely non-conserved and thus not susceptible to cyclocarbonylation inactivation. This provided highly selective inhibition of Mtbc proteasomes while leaving host proteasomal activity unaffected [13]. Interestingly, in this study, the selected hits ZINC3875469, ZINC4076131, and ZINC1883067 were found to interact with Thr1 residues of the Mtbc proteasome.
Figure 2. Interacting residues of Mtb proteasome (monomer; K-chain) with ZINC3875469 (a), ZINC4076131 (b), ZINC1883067 (c), and HT1171 (d).

We also performed the molecular docking of selected hits with the dimer model (K and L chains) of the Mtb proteasome to determine possible interactions with the adjacent chain (L-chain). Asp124 of the adjacent chain of the Mtb proteasome has been reported as an important residue for inhibitor interaction [28]. Interestingly, in addition to interacting with K-chain residues, ZINC3875469 and ZINC4076131 interacted with several other Mtb proteasome L-chain residues including the Asp124 (Figure 3a,c). Despite the fact that ZINC1883067 did not interact with the Asp124 residue of the L-chain, it did interact with several other residues of both chains of the Mtb proteasome (Figure 3b).

The BE values for hits ZINC3875469, ZINC4076131, and ZINC1883067 with the Mtb proteasome were found to be $-7.19$, $-7.95$, and $-7.21$ kcal/mol, respectively, for the monomer, and $-8.05$, $-9.10$, and $-7.07$ kcal/mol, respectively, for the dimer (Table 1).

HT1171 is a well-characterized inhibitor of the Mtb proteasome [13], which was used as the control compound in this study. HT1171 has been reported to bind with Thr1, Thr21, Arg19, Ser20, Val31, and Ala49 residues of Mtb proteasome [27]. Interestingly, Thr1, Ser20, and Thr21 are the common interacting residues of the Mtb proteasome with HT1171 and the selected hit compounds in this study (Figure 2a–d). BE of HT1171 against the Mtb proteasome was noted as $-5.83$ kcal/mol for the monomer and $-5.97$ kcal/mol for the dimer (Table 1).
study, the selected hits ZINC3875469, ZINC4076131, and ZINC1883067 were found to interact with Thr1 residues of the Mtb proteasome. We also performed the molecular docking of selected hits with the dimer model (K and L chains) of the Mtb proteasome to determine possible interactions with the adjacent chain (L chain). Asp124 of the adjacent chain of the Mtb proteasome has been reported as an important residue for inhibitor interaction [28]. Interestingly, in addition to interacting with K-chain residues, ZINC3875469 and ZINC4076131 interacted with several other Mtb proteasome L-chain residues including the Asp124 (Figure 3a,c). Despite the fact that ZINC1883067 did not interact with the Asp124 residue of the L-chain, it did interact with several other residues of both chains of the Mtb proteasome (Figure 3b).

Figure 3. Interacting residues of Mtb proteasome (dimer; K and L chains) with ZINC3875469 (a), ZINC1883067 (b), and ZINC4076131 (c).

The hydrophobic interaction and H-bond help to elucidate the potency of inhibitors to the target protein and contribute an important role in “inhibitor–protein” complex stability [29,30]. The Mtb proteasome residues involved in H-bond (Table 2) and hydrophobic interaction with selected compounds are shown in Figure 4.

Table 1. Binding energy of hit compounds with Mtb proteasome (monomer and dimer).

| Compound        | Binding Energy (kcal/mol) | Inhibition Constant (µM) |
|-----------------|---------------------------|--------------------------|
|                 | Monomer | Dimer | Monomer | Dimer |
| ZINC3875469     | −7.19   | −8.05 | 28.9    | 26.54 |
| ZINC4076131     | −7.95   | −9.10 | 43.24   | 0.213 |
| ZINC1883067     | −7.21   | −7.07 | 27.92   | 23.96 |
| HT1171 *        | −5.83   | −5.97 | 45.36   | 47.01 |

*Positive control for Mtb proteasome.

Table 2. H-bond interactions between compounds and the Mtb proteasome (monomer; K-chain).

| S.No. | Target       | Compound     | H-Bond     | H-Bond Length (Å) |
|-------|--------------|--------------|------------|------------------|
| 1.    | ZINC1883067  | THR1:HN-UNK0:O8 | 2.78   |
|       |              | THR1:HG-UNK0:O14 | 2.68   |
|       |              | THR21:HN-UNK0:O15 | 3.06   |
|       |              | SER141:HN-UNK0:O8 | 2.83   |
| 2.    | Mtb proteasome | ZINC4076131 | THR1:HT-UNK0:O2 | 3.17   |
|       |              | ALA49:HN-UNK0:O8 | 2.95   |
| 3.    | ZINC3875469  | THR21:HN-UNK0:O13 | 2.15   |
|       |              | GLY47:HN-UNK0:O3 | 2.49   |
| 4.    | HT1171       | GLY23:HN-UNK0:O6 | 2.71   |
The hydrophobic interaction and H-bond help to elucidate the potency of inhibitors to the target protein and contribute an important role in "inhibitor–protein" complex stability [29,30]. The Mtb proteasome residues involved in H-bond (Table 2) and hydrophobic interaction with selected compounds are shown in Figure 4.

In the docking study, more negative BE corresponded to the strong binding of hits to the target protein. Furthermore, it is a fact that weaker binding will ultimately have a rapid dissociation rate [31]. Accordingly, in this study, the hits (ZINC3875469, ZINC4076131, and ZINC1883067) exhibited lower BE (strong binding) with the Mtb proteasome than the control compound (HT1171), suggesting that these compounds could be utilized as an inhibitor of the Mtb proteasome to combat TB. The results of the pkCSM and SwissADME tool show that top-scored compounds (ZINC3875469, ZINC4076131, and ZINC1883067) retained an acceptable range of ADMET and drug-likeness (Lipinski) (Table 3).
Table 3. Pharmacokinetic properties of top-scoring ligands.

| Property                  | Model Name       | Predicted Value         | Unit       |
|---------------------------|------------------|-------------------------|------------|
|                           | ZINC1883067      | ZINC4076131              | ZINC3875469|
| Absorption                |                  |                         |            |
| Water solubility          | −3.67            | −5.213                  | −4.624     | log mol/L  |
| Caco2 permeability        | −0.275           | 1.432                   | 1.569      | log Papp in 10–6 cm/s |
| Intestinal absorption     | 81.583           | 97.413                  | 96.726     | % Absorbed |
| Skin Permeability         | −2.786           | −2.629                  | −2.985     | log Kp     |
| Distribution              |                  |                         |            |
| VDss (human)              | −0.44            | 0.315                   | 0.397      | log L/kg   |
| Fraction unbound (human)  | 0.173            | 0.118                   | 0.105      | Fu         |
| BBB permeability          | −1.036           | 0.099                   | 0.2        | log BB     |
| CNS permeability          | −2.744           | −1.483                  | −2.42      | log PS     |
| Metabolism                |                  |                         |            |
| CYP2D6 substrate          | No               | No                      | No         |            |
| CYP3A4 substrate          | No               | Yes                     | Yes        |            |
| CYP1A2                    | Yes              | Yes                     | No         | Yes/No     |
| CYP2C19                   | No               | Yes                     | No         |            |
| CYP2C9                    | No               | Yes                     | No         |            |
| CYP2D6                    | No               | No                      | No         |            |
| CYP3A4                    | No               | No                      | No         |            |
| Excretion                 |                  |                         |            |
| Total Clearance           | 0.587            | 0.742                   | 0.636      | log mL/min/kg |
| Renal OCT2 substrate      | No               | No                      | Yes        | Yes/No     |
| AMES toxicity             | Yes              | No                      | No         |            |
| Max. tolerated dose (human)| −0.58           | 0.547                   | −0.423     | log mg/kg/day |
| hERG I inhibitor          | No               | No                      | No         | Yes/No     |
| Oral Rat Acute Toxicity (LD50) | 2.321   | 2.347                   | 1.837      | mol/kg     |
| Oral Rat Chronic Toxicity (LOAEL) | 1.35 | 1.913                   | 1.708      | log mg/kg bw/day |
| Hepatotoxicity            | No               | No                      | No         | Yes/No     |
| Skin Sensitisation        | Yes              | No                      | No         |            |
| T. pyriformis toxicity    | 0.804            | 0.569                   | 1.054      | (log µg/L) |
| Minnow toxicity           | 0.644            | −2.307                  | 0.712      |            |
| Druglikeness              | Lipinski         | Yes                     | Yes        | Yes        | (Yes/No)   |

3.2. MD Simulation

MD simulations of the protein–ligand complex were performed using Gromacs 2020.4 on the Linux platform. MD simulation provides information about the receptor–ligand complex with time, so we performed the MD simulation for 20 ns on the three complexes (hit compounds). After the simulation, we analyzed the trajectory files for RMSD, RMSF, protein–ligand interactions, etc.

3.2.1. RMSD

The RMSD value determines the mean deviation of the complex at a specific time. It is an indicator that defines the average change in an atom’s displacement in the specific molecular conformation of the reference conformation. In trajectory analysis, the complex RMSD was found within the range of 0.25 Å. The initial RMSD value of the complex was 0.1 Å. The backbone atoms were monitored, and the stability, compactness, structural fluctuations, and protein–ligand interactions in a solvated system were examined. RMSD of the backbone was also noted to 0.2 Å (Figure 5). RMSD was found to be constant at 0.2 Å.
after 10 ns. The low RMSD value suggests that complexes are more stable. Moreover, it was noted that among the three complexes, complex ZINC3875469 had the lowest RMSD values. On the other hand, complex ZINC3873067 had a comparatively larger RMSD value. This suggests that complex ZINC3875469 has more stability.

**Figure 5.** RMSD of protein and ligand after the initial RMSD values were stabilized. The RMSD graph for the backbone is shown in black color (complex ZINC1883067), red color (complex ZINC3875469), and green color (complex ZINC4076131).

### 3.2.2. RMSF

The RMSF is useful for characterizing local protein mobility in the protein–ligand complex, which is calculated throughout the simulation. It relates to the root-mean-square displacement of each frame conformation residue relative to the average conformation used to determine the flexibility of a protein region. In an RMSF plot, the peak shows the protein area fluctuates more throughout the simulation, while the lower RMSF values reflect the less conformational transition. The atomic profile fluctuations were found to be almost similar in all three complexes. The analysis revealed that the RMSF plot (Figure 6) displayed minimal fluctuations in the protein structures for complex ZINC3875469. The protein–ligand complex displayed lower flexibility, and the RMSF plot revealed variations in certain regions of protein residues. It is suggested that the ligand binding site remained approximately rigid throughout the simulation.

**Figure 6.** RMSF protein backbone and ligand complex is shown in black color (complex ZINC1883067), red color (complex ZINC3875469), and green color (complex ZINC4076131).
3.2.3. Radius of Gyration (Rg)

Rg is used to assess a characterization parameter that evaluates changes in protein structures. For the measurement of the transition in Rg of the protein backbone atoms, the gmx gyrate software was used. Figure 7 shows that the Rg values of complexes ZINC1883067, ZINC3875469, and ZINC4076131 did not change significantly throughout the simulation and continued to fluctuate at 1.73 and 1.69 nm, respectively, indicating that the ligand had little influence on protein structures. It was observed that the Rg value of complex ZINC3875469 was lower and had little fluctuation comparatively throughout the 20 ns of simulation. This suggests that the ligand–protein interaction in complex ZINC3875469 is very high, which makes its structure more compact.

![Radius of gyration (total and around axes)](image)

**Figure 7.** Plot for Rg of backbone atoms of the proteins in the presence of ligands. Black color (complex ZINC1883067), red color (complex ZINC3875469), and green color (complex ZINC4076131).

3.2.4. Minimum Distance

The minimum distance between protein and ligand is given in Figure 8. The average value was found to be 1.5 nm. Interestingly, complex ZINC3875469 had the comparatively lowest minimum distance of 0.25 nm during the entire simulation, indicating more compactness and stability of complex ZINC3875469. This suggests that complex ZINC3875469 is more stable than other complexes comparatively.

![Minimum Distance](image)

**Figure 8.** Plot showing minimum distance for complexes. Black color (complex ZINC1883067), red color (complex ZINC3875469), and green color (complex ZINC4076131).
3.2.5. Number of Hydrogen Bonds (H-Bond Number)

The number of H-bonds was measured to find out the robustness of the complex using a cut-off value 0.35 nm. It was noticed that complexes ZINC1883067 and ZINC3875469 had the most H-bonds, but the complex ZINC3875469 H-bonds were more stable over the entire simulation and thus play a significant role in stabilizing protein–ligand interactions (Figure 9).

Figure 9. Plot showing number of hydrogen bonds for complexes. Black color (complex ZINC1883067), red color (complex ZINC3875469), and green color (complex ZINC4076131).

It should be noted that the BE values and MD simulations obtained can only show the binding effectiveness and stability of inhibitors with the target protein. However, further bench work studies are required to validate these hits (ZINC3875469, ZINC4076131, and ZINC1883067) as Mtb proteasome inhibitors.

4. Conclusions

In summary, natural compounds from the ZINC database were screened against the Mtb proteasome. The top hit compounds (ZINC3875469, ZINC4076131, and ZINC1883067) demonstrated robust binding with the monomer as well as dimer Mtb proteasome. Molecular docking of these selected hits with the Mtb proteasome dimer model revealed that, in addition to interacting with K-chain residues, they also interacted with many other residues of the L-chain. These results open the way for further experimental confirmation in the quest for a novel Mtb proteasome inhibitor to combat TB.

Author Contributions: Conceptualization, T.M.A., and S.I.; methodology, T.M.A., and S.I.; writing—original draft preparation, T.M.A., and S.I.; writing—review and editing, M.A.S., M.Y.A., I.A., A.M.A., M.J.A., M.A.K., A.S., and M.S. All authors have read and agreed to the published version of the manuscript.

Funding: The authors would like to express their gratitude to the Research Center of Advanced Materials—King Khalid University, Saudi Arabia for support by grant number (RCAMS/KKU/0020/20).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Not available.
References

1. MacNeil, A.; Glaziou, P.; Sismanidis, C.; Maloney, S.; Floyd, K. Global Epidemiology of Tuberculosis and Progress Toward Achieving Global Targets—2017. MMWR Morb. Mortal. Wkly. Rep. 2019, 68, 263–266. [CrossRef]

2. Bloom, B.R.; Atun, R.; Cohen, T.; Dye, C.; Fraser, H.; Gomez, G.B.; Knight, G.; Murray, M.; Nardell, E.; Rubin, E.; et al. Tuberculosis. In Major Infectious Diseases, 3rd ed.; Holmes, K.K., Bertozzi, S., Bloom, B.R., Jha, P., Eds.; The International Bank for Reconstruction and Development/The World Bank: Washington, DC, USA, 2017. [CrossRef]

3. Raviglione, M.C.; Smith, I.M. XDR tuberculosis—Implications for global public health. N. Engl. J. Med. 2007, 356, 656–659. [CrossRef]

4. Saxena, A.K.; Singh, A. Mycobacterial tuberculosis Enzyme Targets and their Inhibitors. Curr. Top Med. Chem. 2019, 19, 337–355. [PubMed]

5. Bibo-Verdugo, B.; Jiang, Z.; Caffrey, C.R.; O'Donoghue, A.J. Targeting proteasomes in infectious organisms to combat disease. FEBS J. 2017, 284, 1503–1517. [CrossRef] [PubMed]

6. Darwin, K.H.; Ehrt, S.; Gutierrez-Ramos, J.C.; Weich, N.; Nathan, C.F. The proteasome of Mycobacterium tuberculosis is required for resistance to nitric oxide. Science 2003, 302, 1963–1966. [CrossRef] [PubMed]

7. Gandotra, S.; Schnappinger, D.; Monteleone, M.; Hillen, W.; Ehrt, S. In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat. Med. 2007, 13, 1515–1520. [CrossRef] [PubMed]

8. Zhai, W.; Wu, F.; Zhang, Y.; Fu, Y.; Liu, Z. The Immune Escape Mechanisms of Mycobacterium Tuberculosis. Molecules 2021, 26, 1003–1019. [CrossRef]

9. Hu, G.; Lin, G.; Wang, M.; Dick, L.; Xu, R.M.; Nathan, C.; Li, H. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. Mol. Microbiol. 2006, 59, 1417–1428. [CrossRef]

10. Yang, S.C.; Chang, S.S.; Chen, H.Y.; Chen, C.Y. Identification of potent EGFR inhibitors from TCM Database@Taiwan. J. Mol. Biol. 2011, 410, 717–730. [CrossRef]

11. Kwon, Y.D.; Nagy, I.; Adams, P.D.; Baumeister, W.; Jap, B.K. Crystal structures of the Rhodococcus proteasome with and without its pro-peptides: Implications for the role of the pro-peptide in proteasome assembly. J. Mol. Biol. 2004, 335, 233–245. [CrossRef] [PubMed]

12. Lin, G.; Li, D.; Chidawanyika, T.; Nathan, C.; Li, H. Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome. Arch. Biochem. Biophys. 2010, 501, 214–220. [CrossRef] [PubMed]

13. Lin, G.; Li, D.; de Carvalho, L.P.; Deng, H.; Tao, H.; Vogt, G.; Wu, K.; Schneider, J.; Chidawanyika, T.; Warren, J.D.; et al. Inhibitors selective for mycobacterial versus human proteasomes. Nature 2009, 461, 621–626. [CrossRef] [PubMed]

14. Rozman, K.; Alexander, E.M.; Ogorevc, E.; Bovzovicar, K.; Sosic, I.; Aldrich, C.C.; Gobec, S. Psoralen Derivatives as Inhibitors of Mycobacterium tuberculosis Proteasome. Molecules 2020, 25, 1305. [CrossRef] [PubMed]

15. Zheng, Y.; Jiang, X.; Gao, F.; Song, J.; Sun, J.; Wang, L.; Sun, X.; Lu, Z.; Zhang, H. Identification of plant-derived natural products as potential inhibitors of the Mycobacterium tuberculosis proteasome. BMC Complement Altern. Med. 2014, 14, 400. [CrossRef] [PubMed]

16. Lin, G.; Li, D.; Chidawanyika, T.; Nathan, C.; Li, H. Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome. Arch. Biochem. Biophys. 2010, 501, 214–220. [CrossRef] [PubMed]

17. Pinzi, L.; Rastelli, G. Molecular Docking: Shifting Paradigms in Drug Discovery. J. Mol. Biol. 2004, 335, 233–245. [CrossRef] [PubMed]

18. Ivanova, L.; Karelson, M.; Dobchev, D.A. Multitarget Approach to Drug Candidates against Alzheimer’s Disease Related to AChE, SERT, BACE1 and GSK3beta Protein Targets. Molecules 2020, 25, 1846. [CrossRef]

19. Sethi, A.; Joshi, K.; Sasikala, K.; Alvala, M. Molecular docking in modern drug discovery: Principles and recent applications. In Drug Discovery and Development—New Advances; IntechOpen : London, UK, 2019; pp. 27–39. [CrossRef]

20. Langdon, S.R.; Westwood, I.M.; van Montfort, R.L.; Brown, N.; Blagg, J. Scaffold-focused virtual screening: Prospective application to the discovery of TTK inhibitors. J. Chem. Inf. Model. 2013, 53, 1100–1112. [CrossRef]

21. Yang, S.C.; Chang, S.S.; Chen, H.Y.; Chen, C.Y. Identification of potent EGFR inhibitors from TCM Database@Taiwan. PLoS Comput. Biol. 2011, 7, e1002189. [CrossRef]

22. Valasani, K.R.; Vangavaragu, J.R.; Day, V.W.; Yan, S.S. Structure based design, synthesis, pharmacophore modeling, virtual screening, and molecular docking studies for identification of novel cyclophilin D inhibitors. J. Chem. Inf. Model. 2014, 54, 902–912. [CrossRef]

23. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [CrossRef]

24. Daina, A.; Micheliin, O.; Zeeot, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717. [CrossRef] [PubMed]

25. Pires, D.E.; Blundell, T.L.; Ascher, D.B. pKCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J. Mol. Chem. 2015, 58, 4066–4072. [CrossRef] [PubMed]

26. MacKerell, A.D., Jr. Atomistic models and force fields. Comput. Biochem. Biophys. 2001, 9, 7–38.

27. Tyagi, R.; Srivastava, M.; Jain, P.; Pandey, R.P.; Asthana, S.; Kumar, D.; Raj, V.S. Development of potential proteasome inhibitors against Mycobacterium tuberculosis. J. Biomol. Struct. Dyn. 2020, 19, 1–15. [CrossRef] [PubMed]

28. Mehra, R.; Chib, R.; Munagala, G.; Yempella, K.R.; Khan, I.A.; Singh, P.P.; Khan, F.G.; Nargotra, A. Discovery of new Mycobacterium tuberculosis proteasome inhibitors using a knowledge-based computational screening approach. Mol. Divers. 2015, 19, 1003–1019. [CrossRef]
29. Shaikh, S.; Zainab, T.; Shakil, S.; Rizvi, S.M. A neuroinformatics study to compare inhibition efficiency of three natural ligands (Fawcettimine, Cernuine and Lycodine) against human brain acetylcholinesterase. *Network* 2015, 26, 25–34. [CrossRef] [PubMed]

30. Rizvi, S.M.; Shaikh, S.; Khan, M.; Biswas, D.; Hameed, N.; Shakil, S. Fetzima (levomilnacipran), a drug for major depressive disorder as a dual inhibitor for human serotonin transporters and beta-site amyloid precursor protein cleaving enzyme-1. *CNS Neurol. Disord. Drug Targets* 2014, 13, 1427–1431. [CrossRef] [PubMed]

31. Copeland, R.A. Conformational adaptation in drug-target interactions and residence time. *Future Med. Chem.* 2011, 3, 1491–1501. [CrossRef] [PubMed]